Table 6 Prior Multi-Center Phase II/III studies on GBCAs for CMR indications
Investigators | Number of study subjects | Year | Journal | Protocol | Contrast agent | mmol/kg | Recommended gadolinium dose |
|---|---|---|---|---|---|---|---|
Wolff et al [17] | 99 | 2004 | Circulation | Perfusion | Gadopentetate Dimeglumine | 0.05; 0.10; 0.15 | 0.05 mmol/kg |
Giang et al [18] | 94 | 2004 | Eur Heart J | Perfusion | Gadopentetate Dimeglumine | 0.05; 0.10; 0.15 | 0.10 or 0.15 mmol/Kg |
Kim et al [16] | 566 | 2008 | Circulation | LGE | Gadoversetamide | 0.5, 0.1, 0.2 or 0.3 | 0.2 mmol/kg |